financetom
Business
financetom
/
Business
/
Canadian National Railway Proposes New Contract Offer to Teamsters Canada Rail Conference
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Canadian National Railway Proposes New Contract Offer to Teamsters Canada Rail Conference
May 16, 2024 10:18 AM

12:54 PM EDT, 05/16/2024 (MT Newswires) -- Canadian National Railway ( CNI ) said Thursday it proposed a new contract offer to the Teamsters Canada Rail Conference.

As part of the offer, the company has offered to schedule days off and pay a higher rate for any work over 10 hours in a shift with a maximum of 12 hours per shift for employees in Western Canada.

The company said this complies with the maximum on-duty period under the Duty and Rest Period Rules.

Also, all staffers would keep their existing 10 paid leave days, their existing 10 paid medical leave days, their existing vacation allotment, their existing statutory holidays, and their rest at their home terminal.

Other changes include wage increases of 3% in 2024 and 2.5% in 2025 and other monetary improvements.

Among other things, the Duty and Rest Period Rules require that employees cannot work more than 60 hours per seven-day period or more than 192 hours per 28-day period. Employees must also receive a "reset break" of at least two consecutive nights rest undisturbed every seven days.

The news follows the ratification of a tentative agreement between CNTL, a CN subsidiary involved in first and last-mile trucking container pickup and deliveries, and owner-operators affiliated with Unifor. This four-year agreement covers 750 owner-operators under contract with CNTL in Canada until Dec. 31, 2027.

The railway's shares were last seen up $0.70 to $171.38 on the Toronto Stock Exchange.

Price: 171.33, Change: +0.65, Percent Change: +0.38

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Brookdale Senior Living Reports Increase in December Occupancy
Brookdale Senior Living Reports Increase in December Occupancy
Jan 9, 2025
05:22 PM EST, 01/09/2025 (MT Newswires) -- Brookdale Senior Living ( BKD ) said Thursday that December weighted average occupancy rose 100 basis points year-over-year to 79.3%. The Q4 weighted average occupancy rose 100 basis points from a year earlier and 50 basis points from Q3, the company said. ...
Block's Ticker Symbols to Change on NYSE and ASX
Block's Ticker Symbols to Change on NYSE and ASX
Jan 9, 2025
05:19 PM EST, 01/09/2025 (MT Newswires) -- Block (SQ) said Thursday it will change its ticker symbols from SQ and SQ2 to XYZ. The ticker changes on the company's dual listings on the New York Stock Exchange and the Australian Securities Exchange are effective Jan. 21. Block's common shares will start trading under the new symbol effective Jan. 22, according...
Repare Therapeutics to Refocus Resources on Advancing 2 Phase 1 Clinical Trials
Repare Therapeutics to Refocus Resources on Advancing 2 Phase 1 Clinical Trials
Jan 9, 2025
05:23 PM EST, 01/09/2025 (MT Newswires) -- Repare Therapeutics ( RPTX ) said late Thursday it is refocusing its resources on advancing phase 1 clinical programs for RP-1664 in solid tumors and RP-3467 in certain types of cancer. The company also intends to seek partnerships for lunresertib and camonsertib before starting the next trials. The strategic realignment, combined with cost...
Intellia Therapeutics to Workforce by 27%, Halt Some Programs
Intellia Therapeutics to Workforce by 27%, Halt Some Programs
Jan 9, 2025
05:24 PM EST, 01/09/2025 (MT Newswires) -- Intellia Therapeutics ( NTLA ) plans to cut its workforce by 27% to cuts costs and stop development of NTLA-3001 to treat alpha-1 antitrypsin deficiency-associated lung disease and halt some research-stage programs. Resources will be focused on NTLA-2002 for hereditary angioedema and nexiguran ziclumeran for transthyretin amyloidosis, the company said Thursday in a...
Copyright 2023-2026 - www.financetom.com All Rights Reserved